1AI Financials: Results, Ratios & Statements | Algorae Pharmaceuticals

1AI

Algorae Pharmaceuticals

Pharmaceuticals, Biotechnology & Life Sciences

Algorae Pharmaceuticals Limited focuses on the development and commercialization of innovative pharmaceuticals and biotechnology products. The company leverages cutting-edge research to address unmet medical needs across various therapeutic areas. Its market position is bolstered by a robust pipeline of drugs that target specific industry demands, making it a key player in pharmaceutical innovation.

Short position

short percentage0.00%

reported shorts16.8K

shares on issue2.028B

Algorae Pharmaceuticals (ASX:1AI) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 16,823 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. 1AI is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue: $77.7K (source: ASX (Markit))vs $141.1K (source: ASX (Markit)) (FY25); ASX (Markit), as at 29 Sep 2026
NPAT: −$2.7M (source: ASX (Markit))vs −$803.0K (source: ASX (Markit)) (FY25); ASX (Markit), as at 29 Sep 2026
EPS (diluted): −$0.002vs −$0.001 (FY25); Yahoo Finance, as at 29 Sep 2026

Rev YoY: −44.9%FY
EPS YoY: n/aFY

ASX (Markit)

Summary of Appendix 4E and 2026 Annual Report, 31 Aug 2026

Algorae Pharmaceuticals reported a net loss after tax of $2.71 million for FY2026, a 238% increase from the prior year's loss of $0.80 million, with total revenue and other income falling 45% to $77,667. No dividends were paid or declared. The company is transitioning from a pure R&D business to a dual-track model combining AI-driven drug discovery and pharmaceutical commercialisation, having executed five commercial agreements and lodged its first TGA registration dossier, though no product revenue was recognised during the year.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026

Gross margin: n/a
Operating margin: n/a
Net margin: −3,490.0%
FCF margin: n/a
ROE: n/a
ROA: n/a
FCF conversion: n/a
Net debt (excl. leases): n/a
Net debt / EBITDA: n/a
Current ratio: n/a
Interest cover: n/a
Cash dividends paid / net profit: n/a
Market cap: n/a (no share count we can vouch for)
P/E: n/a
P/B: n/a (no share count we can vouch for)

Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

1AI income, newest period first, figures in AUD
Line item	FY26	FY25	FY24	FY23
Revenue	$77.7K (source: ASX (Markit))	$141.1K (source: ASX (Markit))	$125.2K (source: ASX (Markit))	$42.0K (source: ASX (Markit))
Operating income	n/a	n/a	−$2.2M	−$2.1M
EBITDA	n/a	n/a	−$2.2M	−$2.1M
EBIT	n/a	n/a	−$2.2M	−$2.1M
Pretax income	n/a	n/a	−$2.1M	−$2.1M
Tax	n/a	n/a	$0	$0
NPAT	−$2.7M (source: ASX (Markit))	−$803.0K (source: ASX (Markit))	−$2.1M	−$2.1M
Net interest income	n/a	n/a	$125.2K	$42.0K
EPS basic	−$0.002	−$0.001	−$0.001	−$0.002
EPS diluted	−$0.002	−$0.001	−$0.001	−$0.002
Shares	n/a	n/a	1.69B	1.56B

ASX (Markit)

Financial reports

The company's own filings, newest first

Showing 10 of 99 reports